This is a profound book that comprehensively discusses a malignant disorder characterized by the proliferation of plasma cells and is commonly known as Multiple Myeloma. Extensive insight has been acquired into the molecular pathways that lead to this disorder and needless to say, much more remains to be done and the comprehension of these pathways is closely connected to their therapeutic implications. Currently, the introduction of latest agents like thalidomide and liposomal doxorubicin has resulted in an outbreak of trials targeted at testing several combinations for the purpose of enhancing survival. Greater reaction rates seen with these agents have resulted in their admission into induction therapies. The role of several novel therapies in relation to transplantation has also been evaluated along with the latest progresses in the management of renal dysfunction, mobilization of stem cells, dentistry, etc. in the context of this disease. The aim of this book is to serve as a concise and comprehensive source of reference on multiple myeloma for a wide spectrum of readers.